A multitude of new anticoagulant and antiplatelet agents have been introduced in recent years. Although some of these agents are pharmacologically reversible, many are not. The site of metabolism and halflife differs by agent, so discontinuation parameters can vary widely. Many of our cataract surgical colleagues ignore systemic anticoagulation with impunity. After all, cataract surgery is typically a bloodless procedure. Modern transconjunctival vitreoretinal surgery, particularly macular cases including epiretinal membranes and macular holes, are much less invasive than in the past. Yet other vitreoretinal procedures, such as scleral buckling or vitrectomy for diabetic tractional retinal detachment, can have dire consequences with significant bleeding. Evidence-based guidance is needed.
In this edition of Practical Retina, Dimosthenis Mantopoulos, MD, from Ohio State University, and Demetrios G. Vavvas, MD, PhD, from the Massachusetts Eye and Ear Infirmary, provide a roadmap for the vitreoretinal surgeon to navigate the new landscape of anticoagulant and antiplatelet agents. They provide a handy guide regarding the metabolism and discontinuation parameters for these medications and delve into the available literature regarding their use and risks during ophthalmic surgery.
Vitreoretinal surgeons are frequently faced with the preoperative decision of whether to hold an anticoagulant or antiplatelet agent. In collaboration with the patient's primary medical team, the surgeon must balance the urgency of the case, the likelihood of intraoperative hemorrhage, and the systemic risks to holding the medication. Therefore, this review by Drs. Mantopoulos and Vavvas is sure to be of high interest to the vitreoretinal surgical community.
Thanks to the latest technical advances that have made vitrectomy surgery a much safer, less-invasive, and faster procedure, its frequency has increased by 31% during the last decade. The incidence of vitrectomy surgery, according to a recent populationbased study, was 1.92 per 1,000 enrollees. 1 At the same time, the use of antiplatelet (AP) drugs (eg, aspirin, and clopidogrel [Plavix; Bristol-Myers Squibb, New York, NY]) and anticoagulant (AC) drugs (eg, heparin, warfarin, rivaroxaban [Xarelto; Janssen, Beerse, Belgium], apixaban, and dabigatran [Pradaxa; Boehringer Ingelheim, Ridgefield, CT]) has dramatically increased in older adults, 2-5 the population most common to undergo vitreoretinal surgery. Given the high frequency of use and inherent risks of these medications, other surgical specialties have established guidelines to optimize perioperative management. 6, 7 However, in ophthalmology, there are conflicting data about the sequelae of these drugs, [8] [9] [10] and a final consensus has not yet been reached, with the exception possibly of in the subspecialty of oculoplastics.
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No definitive guidelines have been published related to perioperative management of anticoagulants in the field of vitreoretinal surgery, but according to a study conducted in Britain, 81% of the surgeons would consider stopping warfarin prior to vitreoretinal surgery based on the international normalized ratio (INR), 12 and Chandra et al. found that use of oral anticoagulants was a risk for suprachoroidal hemorrhage. 13 Yet a study by Ryan et al. 14 Practical Retina rhage or serious complications, despite a quarter of patients exhibiting some form of bleeding. Similar conclusions were reached by Brown and Mahmoud in a retrospective comparative cohort study of 97 patients with diabetic retinopathy, whereas there was no difference in perioperative complications related to anticoagulation. 15 Dayani and Grand 16 found that only supratherapeutic levels of INR were related to increased risk of hemorrhage, but no serious complications were seen. Kallio et al. concluded that use of oral anticoagulants did not predispose to hemorrhage associated with peri/retrobulbar blocks.
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REASONS TO DISCONTINUE
The concern for unexpected intraoperative hemorrhages during vitreoretinal surgery secondary to these drugs was raised in a case series back in 1996. 18 Subsequent studies concluded that both the antiplatelet and anticoagulation medications might increase the risk of suprachoroidal hemorrhage, 13 persistent vitreous hemorrhage, and reoperation. 19 However, not all the groups reached similar conclusions. Narendran et al. 9 performed a prospective controlled study and concluded that aspirin was safe, but the association of warfarin with any bleeding was statistically significant (with an associated risk ratio of 6.185). The opposite was observed by Passemard et al., 8 who performed a retrospective controlled study with 206 patients receiving AP or AC medications. In that study, the authors found that the risk of severe hemorrhagic complications was high in the AP group (nine of 44 patients), but not in the group treated with AC (P = .031). Interestingly, Brown et al. 15 noted that patients undergoing diabetic pars plana vitrectomy while on AC or AP had a significantly lower postoperative visual acuity (20/230 versus 20/100 in control group; P = .03), even though there was not a statistically significant difference in the risk of intraoperative or postoperative vitreous hemorrhage. Therefore, the authors hypothesized that this surprising outcome was due to the underlying vascular damage in the eyes of patients receiving treatment with AC and AP.
REASONS TO NOT DISCONTINUE
Other studies found that treatment with AC/AP drugs did not impair the final outcome in eyes that underwent vitrectomy and/or scleral buckle. The study with the largest sample size (239 eyes from 
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patients receiving AC and/or AP versus 583 eyes in control group) found that AC use, but not AP use, was associated with higher risk of bleeding on postoperative day 1 (P = .03). Nevertheless, there were no serious consequences for the patients with these complications. 10 Chandra et al. focused on the risks of warfarin use in vitreoretinal surgery and did not find a significant difference with the control group. The exception to this conclusion was the subgroup of patients with rhegmatogenous retinal detachment who had a higher incidence of vitreous hemorrhage (P = .04) 12 Other large prospective and retrospective studies from different centers failed to correlate the use of AC/AP with increased risk of hemorrhage, and the authors concluded that these drugs can safely be continued by the vitreoretinal surgeon in the perioperative period. [20] [21] [22] Some ophthalmologists are hesitant to proceed with retrobulbar block and vitreoretinal surgery in patients with high international normalized ratio (INR) while on warfarin. Interestingly, Dayani et al. 16 divided their patients in four study groups based on the INR, from subtherapeutic (INR < 1.49) to supratherapeutic (INR > 2.49) and the results showed that patients can safely undergo retrobulbar block and vitreoretinal surgery while on therapeutic levels of warfarin. On the other hand, Malik et al. suggested that in those patient groups where the concern for retrobulbar hemorrhage remains high, due to the aforementioned drugs, subconjunctival anesthesia might be a safer alternative.
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THE CASE WITH INTRAVITREAL INJECTIONS
Patients treated with intravitreal injections frequently report persistent subconjunctival hemorrhage after their office visits. However, given that the pars plana is a relatively avascular area, the concern for severe intraocular hemorrhage remains low. Indeed, in a retrospective case series that included 4,360 anti-vascular endothelial growth factor (VEGF) injections, none of the patients treated with AC/AP or the control group had a vitreous, choroidal, or submacular hemorrhage.
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VITRECTOMY IN THE ERA OF NOVEL ANTICOAGULANTS
The use of vitamin K antagonists, like warfarin, requires strict monitoring of the INR levels, something that can limit some patients' quality of life and increase their dissatisfaction with the treatment. For this reason, as well as to optimize the anticoagulant properties of these agents, several novel drugs have been introduced lately. Despite a single report on a spontaneous vitreous hemorrhage related to rivaroxaban, 24 our knowledge about this drug's hemorrhagic ocular side effects remains limited. Grand et al. 25 recently published the first study with patients having vitreoretinal surgery while on "novel oral anticoagulant therapy". In that study, four of 36 eyes (11%) of patients receiving rivaroxaban, apixaban, dabigatran, and prasugrel (Effient; Eli Lilly, Indianapolis, IN) had postoperative vitreous hemorrhage, but none of them had orbital, suprachoroidal, subretinal, or other intraoperative hemorrhage. Thus, the authors concluded that patients taking novel oral anticoagulants can safely undergo vitreoretinal surgery while actively being treated with those drugs.
CONCLUSION
Even though the risk of unexpected hemorrhage in patients receiving AC or AP is present, there is evidence that, in most vitreoretinal surgical cases, the risk is quite low and typically does not lead to irreversible vision loss. This could be due to the fact that, according to the literature, the most common site of hemorrhage is the vitreous cavity rather than the subretinal space, the choroid, or the orbit. Moreover, some studies suggest that even in the patients with postoperative hemorrhage, the need for reoperation remains essentially unchanged. 10 In any case, perioperative management of vitreoretinal patients is part of the art of being a surgeon. Surgeons need to balance three major factors: First is whether the case is emergent or nonemergent. In nonemergent cases, there is more time to hold an AP/AC agent. In emergent cases, a decision must often be reached whether to accept the bleeding risk, attempt to reverse the agent, or delay the case. Second is whether the systemic risk of holding the AP/AC agent is high or low. If there is significant systemic risk to holding anticoagulation, consideration can be given to bridging the patient with low molecular weight heparin if acceptable to the primary physician and/or cardiologist versus proceeding with surgery. The third major consideration is the likelihood of encountering bleeding during the procedure. For instance, a repair of a complex diabetic tractional retinal detachment may be more likely to pose a bleeding risk than vitrectomy for small retained lens fragments, which may affect surgical decision-making. Involving the patient and his or her primary medical team who prescribe the AP/AC agent is an important step in the decision-making process. Vitreoretinal surgeons should be comforted that in most operative cases that must be performed in the setting of AP/AC agents, the scientific evidence indicates the risk of a sightthreatening bleeding episode remains quite low.
